Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: NR4A2

Summary for NR4A2

Gene information	Gene symbol	NR4A2
	Ensembl ID	ENSG00000153234
	Entrez ID	4929
	Gene name	nuclear receptor subfamily 4 group A member 2
	Synonyms	HZF-3\|NOT\|NURR1\|RNR1\|TINUR
	Gene type	protein_coding
	UniProtAcc	P43354

Top

Dataset with differentially expressed gene: NR4A2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.383663	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.700418	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.595759	2.29e-10
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.7601	3.68e-08
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.313017	1.89e-18
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.72621	2.80e-45
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.578637	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.821269	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.670954	1.76e-27
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.297765	5.88e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.357407	2.70e-02
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.876309	1.16e-34
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.490044	5.69e-23
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.439661	5.63e-05
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	0.287432	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.428958	1.15e-25
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.906808	6.46e-12
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.71891	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.88335	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.308031	2.70e-13
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.328944	1.93e-07
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.287306	2.05e-30
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.320036	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.10776	2.20e-35
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.32248	8.10e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.349394	6.20e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.03364	1.43e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	-0.290467	5.99e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.953383	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-0.358135	3.39e-28
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.798807	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.809825	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.334138	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.533976	2.50e-34
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-1.21505	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.455818	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.473962	3.91e-39
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.44895	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.97429	8.08e-24
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.798561	2.43e-42
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.527796	1.66e-32
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.353379	6.61e-05
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	0.253289	8.77e-15
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.412785	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.539994	0.00e+00

Top

Expression of NR4A2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to NR4A2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating NR4A2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
NR4A2	hsa-miR-6867-5p	100	NM_006186
NR4A2	hsa-miR-5692a	99.7071	NM_006186
NR4A2	hsa-miR-8068	99.425	NM_006186
NR4A2	hsa-miR-4423-3p	97.2847	NM_006186
NR4A2	hsa-miR-524-5p	97.135	NM_006186
NR4A2	hsa-miR-520d-5p	97.135	NM_006186
NR4A2	hsa-miR-2054	96.3724	NM_006186
NR4A2	hsa-miR-12136	95.6687	NM_006186
NR4A2	hsa-miR-5582-5p	95.6568	NM_006186
NR4A2	hsa-miR-6832-3p	95.1684	NM_006186
NR4A2	hsa-miR-3529-3p	94.4904	NM_006186
NR4A2	hsa-miR-519e-3p	93.5473	NM_006186
NR4A2	hsa-miR-515-3p	93.5473	NM_006186
NR4A2	hsa-miR-33b-3p	93.5473	NM_006186
NR4A2	hsa-miR-3657	92.8506	NM_006186
NR4A2	hsa-miR-3924	92.4606	NM_006186
NR4A2	hsa-miR-12123	92.4069	NM_006186
NR4A2	hsa-miR-374a-3p	91.9292	NM_006186
NR4A2	hsa-miR-7849-3p	91.8197	NM_006186
NR4A2	hsa-miR-5001-3p	90.3355	NM_006186
NR4A2	hsa-miR-3622a-5p	89.1334	NM_006186
NR4A2	hsa-miR-5195-3p	89.1298	NM_006186
NR4A2	hsa-miR-145-5p	89.1298	NM_006186
NR4A2	hsa-miR-922	89.0143	NM_006186
NR4A2	hsa-miR-10399-5p	88.2641	NM_006186
NR4A2	hsa-miR-6504-3p	88.2641	NM_006186
NR4A2	hsa-miR-30a-5p	87.8839	NM_006186
NR4A2	hsa-miR-30c-5p	87.8839	NM_006186
NR4A2	hsa-miR-30e-5p	87.8839	NM_006186
NR4A2	hsa-miR-30b-5p	87.8839	NM_006186
NR4A2	hsa-miR-30d-5p	87.8839	NM_006186
NR4A2	hsa-miR-8084	87.0534	NM_006186
NR4A2	hsa-miR-365b-3p	86.8988	NM_006186
NR4A2	hsa-miR-365a-3p	86.8988	NM_006186
NR4A2	hsa-miR-580-3p	86.5659	NM_006186
NR4A2	hsa-miR-450b-5p	86.2604	NM_006186
NR4A2	hsa-miR-657	86.1263	NM_006186
NR4A2	hsa-miR-9983-3p	86.03	NM_006186
NR4A2	hsa-miR-361-5p	85.7215	NM_006186
NR4A2	hsa-miR-3926	85.6843	NM_006186
NR4A2	hsa-miR-548av-3p	85.3135	NM_006186
NR4A2	hsa-miR-186-5p	84.1893	NM_006186
NR4A2	hsa-miR-371a-5p	83.9732	NM_006186
NR4A2	hsa-miR-2115-3p	83.3953	NM_006186
NR4A2	hsa-miR-5692c	82.7622	NM_006186
NR4A2	hsa-miR-5692b	82.7622	NM_006186
NR4A2	hsa-miR-5582-3p	82.4304	NM_006186
NR4A2	hsa-miR-129-5p	81.9561	NM_006186
NR4A2	hsa-miR-302e	81.7443	NM_006186
NR4A2	hsa-miR-561-3p	81.6084	NM_006186

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating NR4A2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
NR4A2	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	GCM1; SPDEF (directAnnotation).
NR4A2	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
NR4A2	transfac_pro__M07397	ZNF148 (directAnnotation).
NR4A2	metacluster_131.7	EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; EGR3; EGR3; EGR3; EGR3; EGR4; EGR4; WT1 (directAnnotation). EGR1; EGR1; EGR1; EGR1; EGR1; EGR2; EGR2; EGR2; EGR2; EGR2; EGR3; EGR3; WT1; ZBTB43; ZBTB43; ZBTB43; ZBTB43; ZBTB5; ZBTB5; ZBTB5; ZBTB5; ZBTB7A; ZBTB7A; ZBTB7A; ZBTB7A; ZNF367; ZNF367; ZNF367; ZNF367; ZNF740; ZNF740; ZNF740; ZNF740 (inferredBy_Orthology).
NR4A2	metacluster_131.4	EGR2; EGR2; ZFHX2; ZNF141 (directAnnotation).
NR4A2	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
NR4A2	taipale_cyt_meth__ZNF281_NCCCCTCCCCCN_eDBD_meth	ZNF281 (directAnnotation).
NR4A2	metacluster_15.2	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).
NR4A2	metacluster_7.13	ZFX (directAnnotation).
NR4A2	metacluster_3.11	SP1; SP1; SP2; SP3; SP3; SP4 (directAnnotation).
NR4A2	homer__GGGGGGGG_Maz	MAZ (directAnnotation).
NR4A2	transfac_pro__M01175	ZBTB7B (directAnnotation).
NR4A2	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
NR4A2	tfdimers__MD00151	CHURC1 (directAnnotation).
NR4A2	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
NR4A2	metacluster_15.1	E2F4; E2F4; E2F4; E2F4; E2F7; ZFP69B (directAnnotation). E2F4 (inferredBy_Orthology).
NR4A2	transfac_pro__M01303	SP1 (directAnnotation).
NR4A2	swissregulon__hs__CHD1	CHD1 (directAnnotation).
NR4A2	transfac_pro__M02090	E2F4 (directAnnotation).
NR4A2	transfac_pro__M01714	KLF15 (directAnnotation).
NR4A2	metacluster_15.3	E2F1; E2F6; E2F8; E2F8; TFDP1 (directAnnotation). E2F3 (inferredBy_Orthology).
NR4A2	jaspar__MA1122.1	TFDP1 (directAnnotation).
NR4A2	hocomoco__PROX1_HUMAN.H11MO.0.D	PROX1 (directAnnotation).
NR4A2	transfac_pro__M02089	E2F3 (directAnnotation).
NR4A2	metacluster_3.14	WT1; WT1 (directAnnotation).
NR4A2	metacluster_3.4	SP1; SP2; SP2; SP3 (directAnnotation).
NR4A2	metacluster_126.3	LIN28B; LIN28B (directAnnotation).
NR4A2	hocomoco__EGR4_HUMAN.H11MO.0.D	EGR4 (directAnnotation).
NR4A2	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
NR4A2	cisbp__M07938	E2F1 (directAnnotation).
NR4A2	homer__GGCGGGAARN_E2F6	E2F6 (directAnnotation).
NR4A2	transfac_pro__M07436	WT1 (directAnnotation).
NR4A2	transfac_pro__M02281	SP1 (directAnnotation).
NR4A2	taipale_tf_pairs__GCM1_ELF1_GTGCGGGCGGAAGTN_CAP_repr	ELF1; GCM1 (directAnnotation).
NR4A2	kznf__ZNF730_Imbeault2017_RP_RCADE	ZNF730 (directAnnotation).
NR4A2	metacluster_3.3	KLF10; KLF15; KLF16; KLF9; SP1 (directAnnotation).
NR4A2	transfac_pro__M02898	SMAD3 (directAnnotation).
NR4A2	transfac_public__M00491	PATZ1 (directAnnotation).
NR4A2	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
NR4A2	cisbp__M08198	ELF1 (directAnnotation).
NR4A2	hdpi__TP73	TP73 (directAnnotation).
NR4A2	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
NR4A2	transfac_pro__M04826	EP300 (directAnnotation).
NR4A2	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
NR4A2	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
NR4A2	transfac_pro__M04950	EGR1 (directAnnotation).
NR4A2	hdpi__FLI1	FLI1 (directAnnotation).
NR4A2	transfac_pro__M00652	NRF1 (directAnnotation).
NR4A2	taipale_tf_pairs__ETV5_FOXI1_RSCGGATGTTGN_CAP	ETV5; FOXI1 (directAnnotation).
NR4A2	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).

Page: 1 2 3 4 5 6 7 8 9 10

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
NR4A2	taipale__NR4A2_full_AGGTCANNNNNTGACCT_repr	up	Plasma cells	GSE169246_PacTissue	pre

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."